Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies

Authors

Publication/Presentation Date

11-2008

Volume

112

Issue

11

First Page

4033

Last Page

4033

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article

Share

COinS